Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1389202916666150317232930 http://scihub22266oqcxt.onion/10.2174/1389202916666150317232930 C4460220!4460220!26069456     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Genomics 2015 ; 16 (3): 159-74 Nephropedia Template TP {{tp|p=26069456|t=2015. Management of Incidental Findings in the Era of Next-generation Sequencing |pdf=|usr=}}{{26069456}} gab.com Text Management of Incidental Findings in the Era of Next-generation Sequencing JO: Curr Genomics http://www.kidney.de/pget.php?&tw=1&pmid=26069456 #FOAvip Next-generation sequencing (NGS) technologies allow for the generation of whole exome or whole genome sequencing data, which can be used to identify novel genetic alterations associated with defined phenotypes or to expedite discovery of functional variants for improved patient care. Because this robust technology has the ability to identify all mutations within a genome, incidental findings (IF)- genetic alterations associated with conditions or diseases unrelated to the patient?s present condition for which current tests are being performed- may have important clinical ramifications. The current debate among genetic scientists and clinicians focuses on the following questions: 1) should any IF be disclosed to patients, and 2) which IF should be disclosed ? actionable mutations, variants of unknown significance, or all IF? Policies for disclosure of IF are being developed for when and how to convey these findings and whether adults, minors, or individuals unable to provide consent have the right to refuse receipt of IF. In this review, we detail current NGS technology platforms, discuss pressing issues regarding disclosure of IF, and how IF are currently being handled in prenatal, pediatric, and adult patients. Twit Text FOAVip Management of Incidental Findings in the Era of Next-generation Sequencing ????Curr Genomics http://www.kidney.de/pget.php?&tw=1&pmid=26069456 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26069456 #FOAvip English Wikipedia <ref>{{Cite pmid|26069456}}</ref> Management of Incidental Findings in the Era of Next-generation Sequencing #MMPMID26069456 Blackburn HL; Schroeder B; Turner C; Shriver CD; Ellsworth DL; Ellsworth RE Curr Genomics 2015[Jun]; 16 (3): 159-74 PMID26069456show ga Next-generation sequencing (NGS) technologies allow for the generation of whole exome or whole genome sequencing data, which can be used to identify novel genetic alterations associated with defined phenotypes or to expedite discovery of functional variants for improved patient care. Because this robust technology has the ability to identify all mutations within a genome, incidental findings (IF)- genetic alterations associated with conditions or diseases unrelated to the patient?s present condition for which current tests are being performed- may have important clinical ramifications. The current debate among genetic scientists and clinicians focuses on the following questions: 1) should any IF be disclosed to patients, and 2) which IF should be disclosed ? actionable mutations, variants of unknown significance, or all IF? Policies for disclosure of IF are being developed for when and how to convey these findings and whether adults, minors, or individuals unable to provide consent have the right to refuse receipt of IF. In this review, we detail current NGS technology platforms, discuss pressing issues regarding disclosure of IF, and how IF are currently being handled in prenatal, pediatric, and adult patients. äManagement of Incidental Findings in the Era of Next-generation Sequen(epmc).pdf DeepDyve Pubget Overpricing